Aldeyra Therapeutics, Inc.

Form 3

May 01, 2014

FORM 3 UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549

OMB APPROVAL

OMB Number:

3235-0104

Expires:

response...

January 31, 2005

0.5

Estimated average burden hours per

SECURITIESFiled pursuant to Section 16(a) of the Securities Exchange Act of 1934,

INITIAL STATEMENT OF BENEFICIAL OWNERSHIP OF

Section 17(a) of the Public Utility Holding Company Act of 1935 or Section

30(h) of the Investment Company Act of 1940

(Print or Type Responses)

1. Name and Address of Reporting 2. Date of Event Requiring 3. Issuer Name and Ticker or Trading Symbol Person * Statement Aldeyra Therapeutics, Inc. [ALDX] **JOHNSON & JOHNSON** (Month/Day/Year) 05/01/2014 (Last) (First) (Middle) 4. Relationship of Reporting 5. If Amendment, Date Original Person(s) to Issuer Filed(Month/Day/Year) ONE JOHNSON & JOHNSON (Check all applicable) **PLAZA** (Street) 6. Individual or Joint/Group _X__ 10% Owner Director Officer _Other Filing(Check Applicable Line) (give title below) (specify below) Form filed by One Reporting Person **NEW** _X_ Form filed by More than One BRUNSWICK. NJÂ 08933 Reporting Person (City) (State) (Zip) Table I - Non-Derivative Securities Beneficially Owned 4. Nature of Indirect Beneficial 1. Title of Security 2. Amount of Securities Beneficially Owned Ownership Ownership (Instr. 4) (Instr. 5) (Instr. 4) Form: Direct (D) or Indirect (I) (Instr. 5) Reminder: Report on a separate line for each class of securities beneficially SEC 1473 (7-02) owned directly or indirectly. Persons who respond to the collection of information contained in this form are not

Table II - Derivative Securities Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)

required to respond unless the form displays a

currently valid OMB control number.

1. Title of Derivative Security (Instr. 4)	2. Date Exercisable and Expiration Date (Month/Day/Year)		3. Title and Amount of Securities Underlying Derivative Security (Instr. 4)		or Exercise I	5. Ownership Form of Derivative	6. Nature of Indirect Beneficial Ownership (Instr. 5)
	Date Exercisable	Expiration Date	Title	Amount or Number of Shares	Derivative Security	Security: Direct (D) or Indirect (I)	

						(Instr. 5)	
Series A Preferred Stock	(2)	(2)	Common Stock	915,366	\$ <u>(2)</u>	I	By Johnson & Johnson Development Corporation (1)
Non-Voting Series A Preferred Stock	(2)	(2)	Common Stock	247,694	\$ <u>(2)</u>	I	By Johnson & Johnson Development Corporation (1)
Series B Preferred Stock	(2)	(2)	Common Stock	427,591	\$ <u>(2)</u>	I	By Johnson & Johnson Development Corporation (1)
Non-Voting Series B Preferred Stock	(2)	(2)	Common Stock	133,827	\$ <u>(2)</u>	I	By Johnson & Johnson Development Corporation (1)
Series B Preferred Stock Warrant (Right to Buy)	(2)(3)	12/20/2017	Common Stock	36,345	\$ <u>(2)</u> <u>(3)</u>	I	By Johnson & Johnson Development Corporation (1)
Series B Preferred Stock Warrant (Right to Buy)	(2)(3)	08/14/2018	Common Stock	36,345	\$ (2) (3)	I	By Johnson & Johnson Development Corporation (1)

Reporting Owners

Reporting Owner Name / Address	Relationships				
Reporting Owner Funder, Funders		10% Owner	Officer	Other	
JOHNSON & JOHNSON ONE JOHNSON & JOHNSON PLAZA NEW BRUNSWICK, NJ 08933	Â	ÂX	Â	Â	
JOHNSON & JOHNSON DEVELOPMENT CORP ET AL ONE JOHNSON & JOHNSON PLAZA NEW BRUNSWICK, NJ 08933	Â	ÂX	Â	Â	

Signatures

Douglas Chia, Secretary of Johnson & Johnson			
**Signature of Reporting Person	Date		
Steven M. Rosenberg, Secretary of Johnson & Johnson Development Corporation	05/01/2014		
**Signature of Reporting Person	Date		

Reporting Owners 2

Explanation of Responses:

- * If the form is filed by more than one reporting person, see Instruction 5(b)(v).
- ** Intentional misstatements or omissions of facts constitute Federal Criminal Violations. See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
- (1) The securities reported as being indirectly beneficially owned by the designated Reporting Person are directly beneficially owned by Johnson & Johnson Development Corporation, a wholly-owned subsidiary of the designated Reporting Person.
- All outstanding shares of the Issuer's preferred stock will automatically convert into Common Stock immediately following declaration of effectiveness of the Issuer's Registration Statement for no additional consideration. Each share of Series A Preferred Stock and Non-Voting Series A Preferred Stock will convert into shares of Common Stock on a 2.3726-for-1 basis and each share of Series B Preferred Stock and Non-Voting Series B Preferred Stock will automatically convert into shares of Common Stock on a 1-for-1 basis.
- All outstanding warrants will be net exercised for shares of the Issuer's Series B Preferred Stock and subsequently will automatically convert into Common Stock following declaration of effectiveness of the Issuer's Registration Statement for no additional consideration. Each share of Series B Preferred Stock will automatically convert into shares of Common Stock on a 1-for-1 basis.

Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, *See* Instruction 6 for procedure. Potential persons who are to respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB number.